NASDAQ:AVLN Avalyn Pharma Q3 2026 Earnings Results & Report $29.59 -2.03 (-6.42%) As of 09:48 AM Eastern Avalyn Pharma reported Q3 2026 earnings on November 12, 2026. The company reported EPS of -$0.6690. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market OpensConference Call12:30 PM ET Avalyn Pharma EPS ResultsActual EPS-$0.6690Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAvalyn Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Avalyn Pharma Q3 2026 Earnings FAQ Did Avalyn Pharma beat earnings estimates for Q3 2026? Avalyn Pharma (NASDAQ:AVLN) reported earnings of -$0.6690 per share for Q3 2026. The report was announced on Thursday, November 12, 2026. Avalyn Pharma Earnings HeadlinesAvalyn Pharma Inc. (AVLN) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference TranscriptNovember 11 at 5:00 PM | seekingalpha.comAvalyn Pharma Inc (AVLN)October 3, 2026 | investing.comTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they did. Before a single vote was counted, the IMF flagged markets as increasingly exposed to a sharp correction, Ray Dalio called conditions a classic bubble, and Peter Schiff said a downturn could hit regardless of the outcome.November 12 at 1:00 AM | USA Capital Gold (Ad)Raymond James Initiates Avalyn Pharma With Outperform Rating, $60 Price TargetOctober 2, 2026 | marketscreener.comMAvalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too PriceySeptember 23, 2026 | finance.yahoo.comAvalyn Publishes Phase 1 Data Supporting Lung-Targeted AP02 In Lung DiseaseSeptember 22, 2026 | rttnews.comSee More Avalyn Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avalyn Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalyn Pharma and other key companies, straight to your email. Email Address About Avalyn PharmaAvalyn Pharma (NASDAQ:AVLN) is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment. They are investigational and have not been approved for use.View Avalyn Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going Away Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
